The Top 10 PharmTech Videos of 2025

Why It Matters

These trends signal where capital, talent, and technology will flow in pharma, shaping product pipelines, compliance strategies, and competitive advantage for the next decade.

Key Takeaways

• Gene‑therapy vectors demand new scalable manufacturing.
• High‑concentration biologics enable at‑home subcutaneous dosing.
• Radiopharmaceuticals face isotope supply and short‑half‑life logistics.
• AI accelerates screening, predictive control, and discovery.
• Quality‑control unit warnings heighten regulatory compliance emphasis.

Pulse Analysis

The surge in advanced therapeutic modalities is redefining pharmaceutical manufacturing. Gene‑editing platforms and AAV vectors require novel upstream processes that balance high purity with scalable yields, prompting the industry’s "CGT 2.0" paradigm. Simultaneously, high‑concentration biologics are engineered for subcutaneous delivery, compressing dosage volumes for patient convenience while introducing formulation hurdles such as viscosity management and stability. Radiopharmaceuticals add another layer of complexity, demanding reliable isotope supply chains and ultra‑rapid logistics to preserve short half‑lives, driving investment in on‑site cyclotrons and decentralized production hubs.

Regulatory scrutiny has intensified as agencies issue more warning letters and draft guidances targeting quality‑control infrastructure and extractables‑leachables assessments. Companies are overhauling quality systems, establishing dedicated QC units, and adopting risk‑based remediation plans to satisfy FDA expectations. The focus on rigorous testing not only mitigates compliance risk but also enhances product safety, a critical factor for therapies with narrow therapeutic windows. This heightened compliance culture is fostering cross‑functional collaboration between regulatory affairs, manufacturing, and analytical teams, accelerating the adoption of standardized data platforms.

Artificial intelligence and machine learning are emerging as strategic levers across the drug development continuum. From in‑silico compound screening to predictive process control, AI reduces cycle times and uncovers novel molecular hypotheses. The integration of digital twins and real‑time analytics enables manufacturers to anticipate deviations before they occur, improving yield and reducing waste. Coupled with mega‑deals that consolidate expertise—such as the $17.5 billion Waters‑Becton Dickinson transaction—these technologies are reshaping the competitive landscape, positioning firms that master both advanced biology and data science for sustained growth.